Galectin reports NAVIGATE biomarker data consistent with clinical benefit; FDA package submitted

GALECTIN THERAPEUTICS INC

In patients with ELF >11.3 (high-risk), new varices occurred in 22.7% on belapectin vs 42.9% on placebo.
PRO-C3, a marker of fibrogenesis, showed >50% reduction from baseline with belapectin 2 mg/kg vs placebo at 18 months.
Belapectin reduced progression of liver stiffness on FibroScan (≥30% increase or ≥5 kPa rise) vs placebo.
No drug-related serious adverse events; discontinuation rates similar to placebo in NAVIGATE.
FDA package submitted; company exploring strategic partnerships and extended cash runway.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.